In Vitro: Doxorubicin induces apoptosis and UPR activation in NSCLC cells, with UPR preconditioning enhancing apoptosis via the eIF2α/mTOR pathway, while Tauroursodeoxycholate inhibits this effect. The gene discussed is EIF2A; the disease is non-small cell lung carcinoma.